导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 21.08% | 253/4773 |
| 近一周 | -1.82% | 761/5462 |
| 近一月 | -7.68% | 3926/5421 |
| 近一季 | -13.02% | 3924/5209 |
| 近半年 | 20.16% | 154/4920 |
| 近一年 | 25.47% | 266/4366 |
| 近两年 | 142.74% | 245/2954 |
| 近三年 | 98.23% | 150/2253 |
| 成立以来 | 68.89% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.77% 3407/4961 |
72.61% 231/5312 |
- - |
- - |
| 2025 | 47.95% 545/4813 |
-0.10% 2057/3635 |
3.55% 992/4076 |
48.35% 381/4524 |
-3.60% 3302/4813 |
| 2024 | 11.17% 1342/3463 |
-4.62% 1723/2808 |
-4.57% 1526/3014 |
15.16% 1799/3129 |
6.06% 556/3463 |
| 2023 | 0.33% 414/2656 |
15.10% 220/2280 |
-1.99% 546/2385 |
-9.51% 1839/2515 |
-1.72% 362/2655 |
| 2022 | -32.79% 1685/2207 |
-20.38% 1542/1919 |
-4.46% 1854/2016 |
-15.82% 1346/2113 |
4.96% 498/2208 |
| 2021 | -3.54% 910/1822 |
-8.68% 1091/1255 |
13.53% 286/1330 |
-11.92% 1282/1466 |
5.63% 280/1822 |
| 2020 | 42.15% 275/1250 |
4.56% 69/1028 |
25.41% 156/1067 |
0.12% 1046/1164 |
8.27% 683/1184 |
| 2019 | - - |
- - |
- - |
- - |
10.00% 173/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华宝科技ETF联接C VS. 长安沪深300非周期A(740101) |